SmallCaps Online Announces Investment Opinion.NEW YORK--(BUSINESS WIRE)--July 13, 1999-- SmallCaps Online LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control Initiates Coverage of Vion Pharmaceuticals, Inc. With a BUY Recommendation Visit SmallCaps Online's Web Site at www.SmallCapsOnline.com for Detailed Report SmallCaps Online LLC announced today that it has initiated coverage of Vion Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : VION) with a BUY recommendation. The full text of this report can be accessed at SmallCaps Online's web site, at www.SmallCapsOnline.com. Excerpts from the report follow: Vion Pharmaceuticals, Inc. ("VION") is a biopharmaceutical company focused on the discovery, development and commercialization of products and technologies for the treatment of cancer. With 61 worldwide patents (16 in U.S.) and an additional 23 patents pending, VION's strong scientific and intellectual property underscores its broad product pipeline and five active R&D programs. VION's lead drug candidate is Promycin(R), in Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for head and neck cancer. Central to its strategy to partner on development and commercialization of its products, VION has partnered with Boehringer Ingelheim on Promycin. VION is also developing a unique drug delivery technology called TAPET Tap´et n. 1. Worked or figured stuff; tapestry. (R) (Tumor Amplified Protein Expression Therapy). TAPET utilizes bioengineered Salmonella bacteria to deliver proteins and prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. converting enzymes to tumor cells, and has exhibited significant anti-tumor activity alone (unarmed, or without drug) in preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. . Triapine (R), in Phase I trials, prevents replication of tumor cells by blocking critical steps in the synthesis of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. . Additional to its development pipeline, VION developed Melasyn (R), the first water-soluble synthetic version of melanin melanin (mĕl`ənĭn), water-insoluble polymer of various compounds derived from the amino acid tyrosine. It is one of two pigments found in human skin and hair and adds brown to skin color; the other pigment is carotene, which contributes , and currently receives royalties from the sales of products using Melasyn. VION successfully partnered with San-Mar Laboratories, a leading manufacturer of private-label cosmetics and pharmaceuticals, for the manufacture and marketing of its Melasyn technology, a partnership that has already begun to generate royalty revenue. We believe that VION is undervalued Undervalued A stock or other security that is trading below its true value. Notes: The difficulty is knowing what the "true" value actually is. Analysts will usually recommend an undervalued stock with a strong buy rating. at this time, given its products and pipeline, the unique TAPET technology, its partnering strategy (and proven ability to secure partnerships), and the potential market for its products. The Company estimates the worldwide market for Promycin, TAPET, and Triapine combined, to exceed $8 billion by targeting the 1.4 million patients who suffer from the cancers on which VION is focusing. We are initiating coverage with a BUY rating, and recommend purchase of VION for those investors tolerant of the risks associated with small cap equity investments. SmallCaps Online LLC is a registered investment advisor Registered Investment Advisor (RIA) is a designation obtainable in the United States by an individual who has registered with the U.S. Securities and Exchange Commission or state regulatory agency (where the primary business is situated or multiple States in some cases) in focused on identifying emerging growth companies in the healthcare and information technology sectors that offer compelling investment opportunities over the long term. By providing comprehensive financial services The examples and perspective in this article or section may not represent a worldwide view of the subject. Please [ improve this article] or discuss the issue on the talk page. , including corporate finance, M&A advisory, strategic partnering and communications consulting, the company positions itself to provide a fully integrated package of value-added services to emerging growth companies. The information in this press release has been obtained from sources that SmallCaps Online LLC believes to be reliable, but the Company does not guarantee its accuracy or completeness. Neither the information nor any opinion expressed constitutes a solicitation by SmallCaps Online LLC for the purchase or sale of any securities. SmallCaps Online LLC and/or any of its affiliates may have performed investment banking, consulting or other services for VION and may solicit investment banking, consulting or other business from, any company mentioned in this release. SmallCaps Online LLC or any of its affiliates or persons associated with SmallCaps Online LLC may at anytime be long or short any of the securities referred to herein and may make purchases or sales thereof while the Company's reports are in circulation or posted on the SmallCaps Online LLC web site at www.SmallCapsOnline.com. This material, or any portion thereof, may not be reproduced without prior permission from SmallCaps Online LLC. SmallCaps Online LLC is not responsible for the contents of this document that is intended for electronic transmission and could be thus subjected to tampering or alteration. Copyright (c) 1999 by SmallCaps Online LLC. All rights reserved. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion